Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020088631 - COMPOSITIONS AND METHODS FOR T CELL ENGINEERING

Publication Number WO/2020/088631
Publication Date 07.05.2020
International Application No. PCT/CN2019/114939
International Filing Date 01.11.2019
IPC
C12N 5/10 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/85 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. [CN]/[CN]
  • SUZHOU GRACELL BIOTECHNOLOGIES CO., LTD. [CN]/[CN]
Inventors
  • WANG, Xinxin
  • JIN, Tao
  • YANG, Chunhui
  • SHI, Zhongdong
  • LIU, Liping
  • SUN, Jing
  • QIU, Shuyi
  • CAO, Wei
Agents
  • AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE
Priority Data
201811297174.301.11.2018CN
201811535338.114.12.2018CN
201811549651.018.12.2018CN
201910492882.006.06.2019CN
PCT/CN2019/10165120.08.2019CN
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR T CELL ENGINEERING
(FR) COMPOSITIONS ET PROCÉDÉS POUR L'INGÉNIERIE DES LYMPHOCYTES T
Abstract
(EN)
Provided is an engineered immune cell and use thereof. The engineered immune cell comprises a CAR or engineered TCR, which CAR or engineered TCR can comprise a first antigen binding domain and a second antigen binding domain. The engineered immune cells, when administered into a subject, can inhibit the host immune cells such as T cells and/or NK cells and enhance the survival and persistence of the engineered immune cells in vivo, thereby exhibiting more effective tumor killing activity.
(FR)
L'invention concerne une cellule immunitaire modifiée et son utilisation. La cellule immunitaire modifiée comprend un CAR ou un TCR modifié, lequel CAR ou TCR modifié peut comprendre un premier domaine de liaison à l'antigène et un second domaine de liaison à l'antigène. Les cellules immunitaires modifiées, lorsqu'elles sont administrées à un sujet, peuvent inhiber les cellules immunitaires hôtes telles que les lymphocytes T et/ou les cellules NK et améliorer la survie et la persistance des cellules immunitaires modifiées in vivo, présentant ainsi une activité tumoricide plus efficace.
Latest bibliographic data on file with the International Bureau